S&P 500   3,136.28 (+0.01%)
DOW   27,906.86 (-0.01%)
QQQ   204.35 (+0.14%)
AAPL   269.31 (+0.90%)
FB   200.82 (-0.26%)
MSFT   151.48 (+0.08%)
GOOGL   1,343.94 (+0.07%)
AMZN   1,742.09 (-0.42%)
CGC   20.15 (-5.35%)
NVDA   214.78 (+1.23%)
MU   47.80 (+2.91%)
BABA   201.21 (+1.24%)
GE   11.02 (+0.27%)
TSLA   350.19 (+3.14%)
T   38.11 (+0.18%)
AMD   39.55 (+1.59%)
ACB   2.52 (-3.82%)
PRI   135.41 (+0.04%)
NFLX   296.13 (-2.11%)
BAC   33.53 (+0.06%)
GILD   66.91 (-0.03%)
DIS   146.15 (-0.04%)
S&P 500   3,136.28 (+0.01%)
DOW   27,906.86 (-0.01%)
QQQ   204.35 (+0.14%)
AAPL   269.31 (+0.90%)
FB   200.82 (-0.26%)
MSFT   151.48 (+0.08%)
GOOGL   1,343.94 (+0.07%)
AMZN   1,742.09 (-0.42%)
CGC   20.15 (-5.35%)
NVDA   214.78 (+1.23%)
MU   47.80 (+2.91%)
BABA   201.21 (+1.24%)
GE   11.02 (+0.27%)
TSLA   350.19 (+3.14%)
T   38.11 (+0.18%)
AMD   39.55 (+1.59%)
ACB   2.52 (-3.82%)
PRI   135.41 (+0.04%)
NFLX   296.13 (-2.11%)
BAC   33.53 (+0.06%)
GILD   66.91 (-0.03%)
DIS   146.15 (-0.04%)
S&P 500   3,136.28 (+0.01%)
DOW   27,906.86 (-0.01%)
QQQ   204.35 (+0.14%)
AAPL   269.31 (+0.90%)
FB   200.82 (-0.26%)
MSFT   151.48 (+0.08%)
GOOGL   1,343.94 (+0.07%)
AMZN   1,742.09 (-0.42%)
CGC   20.15 (-5.35%)
NVDA   214.78 (+1.23%)
MU   47.80 (+2.91%)
BABA   201.21 (+1.24%)
GE   11.02 (+0.27%)
TSLA   350.19 (+3.14%)
T   38.11 (+0.18%)
AMD   39.55 (+1.59%)
ACB   2.52 (-3.82%)
PRI   135.41 (+0.04%)
NFLX   296.13 (-2.11%)
BAC   33.53 (+0.06%)
GILD   66.91 (-0.03%)
DIS   146.15 (-0.04%)
S&P 500   3,136.28 (+0.01%)
DOW   27,906.86 (-0.01%)
QQQ   204.35 (+0.14%)
AAPL   269.31 (+0.90%)
FB   200.82 (-0.26%)
MSFT   151.48 (+0.08%)
GOOGL   1,343.94 (+0.07%)
AMZN   1,742.09 (-0.42%)
CGC   20.15 (-5.35%)
NVDA   214.78 (+1.23%)
MU   47.80 (+2.91%)
BABA   201.21 (+1.24%)
GE   11.02 (+0.27%)
TSLA   350.19 (+3.14%)
T   38.11 (+0.18%)
AMD   39.55 (+1.59%)
ACB   2.52 (-3.82%)
PRI   135.41 (+0.04%)
NFLX   296.13 (-2.11%)
BAC   33.53 (+0.06%)
GILD   66.91 (-0.03%)
DIS   146.15 (-0.04%)
Log in

NASDAQ:EIDX - Eidos Therapeutics Stock Price, Forecast & News

$61.93
+2.32 (+3.89 %)
(As of 12/10/2019 01:50 PM ET)
Today's Range
$59.76
Now: $61.93
$61.93
50-Day Range
$36.29
MA: $49.55
$59.94
52-Week Range
$11.15
Now: $61.93
$61.32
Volume2,038 shs
Average Volume219,132 shs
Market Capitalization$2.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.87
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIDX
CUSIPN/A
CIKN/A
Phone415-887-1471

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.22 per share

Profitability

Net Income$-33,290,000.00

Miscellaneous

Employees28
Market Cap$2.32 billion
Next Earnings Date4/20/2020 (Estimated)
OptionableNot Optionable

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.


Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics Inc (NASDAQ:EIDX) announced its quarterly earnings data on Thursday, October, 31st. The company reported $0.18 EPS for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.48. The company had revenue of $26.69 million for the quarter. View Eidos Therapeutics' Earnings History.

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 20th 2020. View Earnings Estimates for Eidos Therapeutics.

What price target have analysts set for EIDX?

6 analysts have issued 1-year target prices for Eidos Therapeutics' shares. Their forecasts range from $29.00 to $75.00. On average, they expect Eidos Therapeutics' stock price to reach $52.00 in the next twelve months. This suggests that the stock has a possible downside of 15.7%. View Analyst Price Targets for Eidos Therapeutics.

What is the consensus analysts' recommendation for Eidos Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eidos Therapeutics.

Has Eidos Therapeutics been receiving favorable news coverage?

Media stories about EIDX stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eidos Therapeutics earned a news impact score of 1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Eidos Therapeutics.

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), Roku (ROKU), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Micron Technology (MU), bluebird bio (BLUE), DexCom (DXCM), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Intellia Therapeutics (NTLA).

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the folowing people:
  • Dr. Neil Kumar, CEO & Director (Age 40)
  • Dr. Isabella Graef M.D., Founder & Board Advisor (Age 54)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Cameron Turtle, Chief Bus. Officer (Age 29)
  • Dr. Hoyoung Huh, Consultant (Age 50)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

Who are Eidos Therapeutics' major shareholders?

Eidos Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (2.46%), State Street Corp (0.58%), Point72 Asset Management L.P. (0.44%), Alps Advisors Inc. (0.20%), SG Americas Securities LLC (0.11%) and Barclays PLC (0.09%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Cameron Turtle, Christine Siu, Eric Aguiar, Jonathan C Fox, Neil Kumar, Rajeev M Shah and Uma Sinha. View Institutional Ownership Trends for Eidos Therapeutics.

Which major investors are selling Eidos Therapeutics stock?

EIDX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc. and Metropolitan Life Insurance Co NY. Company insiders that have sold Eidos Therapeutics company stock in the last year include Bridgebio Pharma Llc, Cameron Turtle, Christine Siu, Jonathan C Fox and Uma Sinha. View Insider Buying and Selling for Eidos Therapeutics.

Which major investors are buying Eidos Therapeutics stock?

EIDX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Redmile Group LLC, SG Americas Securities LLC, California Public Employees Retirement System, Squarepoint Ops LLC, Barclays PLC, State Street Corp and California State Teachers Retirement System. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Eric Aguiar, Neil Kumar and Rajeev M Shah. View Insider Buying and Selling for Eidos Therapeutics.

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $61.66.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $2.31 billion. The company earns $-33,290,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Eidos Therapeutics employs 28 workers across the globe.View Additional Information About Eidos Therapeutics.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is http://www.eidostx.com/.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]


MarketBeat Community Rating for Eidos Therapeutics (NASDAQ EIDX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Eidos Therapeutics and other stocks. Vote "Outperform" if you believe EIDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel